Janssen seeks approval of Stelara for Crohn’s disease
A biologics license application (BLA) was submitted to the US Food and Drug Administration (FDA), while a Grouped Type II variation/extension application was filed with the European Medicines
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
CGS-200 is a novel high-strength topical formulation of the TRPV1 channel agonist trans-capsaicin combined with hyaluronic acid. It has been designed to deliver long-term desensitization of nerve fibers